PanOptica, Inc. (PanOptica) a privately owned early-stage biotechnology company. It is specialized in novel treatments targeting eye diseases. The company is principally engaged in developing innovative ophthalmic therapeutics for the treatment for eye disease addressing unmet medical needs. In addition, it also focuses on acquiring IND or near-IND stage assets and develop them to human clinical proof of concept. PanOptica is headquartered at Mount Arlington in New Jersey, the US.